Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Animal Health, Inc. (Jaguar Health, Inc.) on April 6, 2016, reporting events that occurred on April 1, 2016. The filing addresses corporate governance changes, specifically the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel and governance matters.
Material Changes
- Board Expansion: The Board of Directors increased its size from five to six members.
- New Director Appointment: John Micek III was appointed as a Class II director, serving until the 2017 annual meeting.
- Committee Assignments: Mr. Micek was appointed Chairperson of the Audit Committee (replacing Mr. Bochnowski) and as a member of the Compensation and Nominating Committees.
- Compensation Grant: Mr. Micek was granted options to purchase 100,177 shares of common stock under the 2014 Stock Incentive Plan.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of material risks and contingencies. Management commentary is limited to the rationale for Mr. Micek's appointment, citing his extensive experience with venture capital-backed healthcare companies and his background as an executive officer and board member of numerous companies.
Investor Verification Checklist
- Verify the vesting schedule and exercise price ($1.58 per share) of the 100,177 stock options granted to John Micek III.
- Confirm the updated composition of the Audit, Compensation, and Nominating Committees as disclosed.
- Review the press release filed as Exhibit 99.1 for additional context on the board expansion.
- Note that this filing does not contain updated financial statements; refer to the most recent 10-K or 10-Q for financial health metrics.